Centre for Commercialization of Regenerative Medicine (CCRM) and Creative Destruction Lab (CDL) invite you to join a Speaker Event and Dinner focusing on The Future of Regenerative Medicine.

The evening will kick off with three keynote speakers who are leaders in the advanced therapies space, followed by a moderated panel featuring innovators on the forefront of regenerative medicine, and ending with a night of networking.

Details

• Date: Tuesday, October 25, 2022
• Registration: 3:30-4:00 PM PT
• Time: 4:00 PM-9:00 PM PT
• Location: Pan Pacific Hotel; 999 Canada Pl #300, Vancouver, BC V6C 3B5
• Ticket Pricing: 
  • Early Bird (until Sept 30): $120
  • General Admission (from Oct 1-18): $200
  • Tickets to this event include two drink tickets during cocktail hour and a three-course plated dinner.

Keynote Speakers

Michael May – President & Chief Executive Officer, Centre for Commercialization of Regenerative Medicine (CCRM)

Michael May is President and CEO of the Centre for Commercialization of Regenerative Medicine (CCRM), a Canadian, not-for-profit that develops technologies, launches new companies, and catalyzes investment in the field of regenerative medicine, including cell and gene therapy. Prior to CCRM, Michael was the President, and co-founder, of Rimon Therapeutics Ltd., a Toronto-based tissue engineering company developing novel medical polymers that possess drug-like activity. Dr. May completed his PhD in Chemical Engineering at the University of Toronto as an NSERC Scholar and was awarded the Martin Walmsley Fellowship for Technological Entrepreneurship.

Ali Tehrani – Venture Partner, Amplitude Ventures

Ali Tehrani co-founded Zymeworks, a phase 3 clinical-stage biotechnology company developing multi-functional protein therapeutics and drug conjugates for the treatment of various forms of HER2+ cancers, in 2003 and led the company from inception to clinical validation, through an IPO on the NYSE, to peak $1.9B valuation and 500 employees across Vancouver Canada and Seattle. Dr. Tehrani has a BASc and M.S. in Biochemistry from the University of Massachusetts Amherst and his PhD in Microbiology and Immunology from the University of British Columbia.

Peter Zandstra – Director, School of BME & Michael Smith Labs, UBC; CSO-CCRM; Founder and CSO Notch Therapeutics

Peter Zandstra is a serial entrepreneur and Founding Director of the School of Biomedical Engineering at the University of British Columbia and is the Director of the Michael Smith Laboratories. Dr. Zandstra founded ExCellThera, an advanced clinical-stage biotechnology company focused on delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, and Notch Therapeutics, the developer of a pipeline of cellular immunotherapies originating from pluripotent stem cells that are specifically engineered to address the underlying biology of complex disease systems. Previously, Dr. Zandstra co-founded the CCRM while a Professor at the University of Toronto and still holds the Chief Scientific Officer position. Earlier this year, Dr. Zandstra was appointed to the 2021 Order of Canada.

CDL Advanced Therapies

CDL has launched a new Advanced Therapies stream for pre-seed and seed-stage ventures at the forefront of biotech. To bring this program to life, CDL has partnered with CCRM, a leader in accelerating the development and commercialization of regenerative medicine-based technologies. Four world-class CDL locations play host to CDL Advanced Therapies – the University of British Columbia, the University of Oxford, the University of Toronto, and the University of Wisconsin-Madison – creating an international network that will foster the next generation of biotech companies.

The Advanced Therapies global stream admits an annual cohort of pre-Seed and Seed stage startups. The program brings together entrepreneurs, investors, and scientists with expertise building scalable companies in a variety of fields related to biology, medicine, and healthcare. Read more